- Generic Name:
- I-suh-TUK-sih-mab - irfc
- Drug Type:
- CD38-directed cytolytic antibody (monoclonal antibody)
- How the Drug is Given:
Indications and Usage
Isatuximab-irfc is FDA approved
- In combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
- In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.
Side effects needing medical attention
The most common adverse reactions were neutropenia, infusion-related reactions, pneumonia, upper respiratory tract infection, and diarrhea. The most common hematology laboratory abnormalities were anemia, neutropenia, abnormally low level of lymphocytes in the blood (lymphopenia), and thrombocytopenia.